## Patrick Veit-Haibach

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6514453/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases, 2023, 26, 240-248.	3.9	21
2	Influence of sarcopenia, clinical data, and 2-[18F] FDG PET/CT in outcome prediction of patients with early-stage adenocarcinoma esophageal cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1012-1020.	6.4	9
3	The clinical consequences of functional adrenal uptake in the absence of cross-sectional mass on FDG-PET/CT in oncology patients. Langenbeck's Archives of Surgery, 2022, 407, 1677-1684.	1.9	1
4	Survival prediction using radiomic signatures in metastatic gastric and esophageal adenocarcinoma (GEA) Journal of Clinical Oncology, 2022, 40, 357-357.	1.6	0
5	Combined 18F-FDG PET/CT Radiomics and Sarcopenia Score in Predicting Relapse-Free Survival and Overall Survival in Patients With Esophagogastric Cancer. Clinical Nuclear Medicine, 2022, 47, 684-691.	1.3	14
6	Diagnostic Accuracy of Cardiac MRI versus FDG PET for Cardiac Sarcoidosis: A Systematic Review and Meta-Analysis. Radiology, 2022, 304, 566-579.	7.3	33
7	Comparison of four clinical prognostic scores in patients with advanced gastric and esophageal cancer Journal of Clinical Oncology, 2022, 40, 4057-4057.	1.6	0
8	How to Design Al-Driven Clinical Trials in Nuclear Medicine. Seminars in Nuclear Medicine, 2021, 51, 112-119.	4.6	17
9	EANM/SNMMI practice guideline for [18F]FDG PET/CT external beam radiotherapy treatment planning in uterine cervical cancer v1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1188-1199.	6.4	23
10	Prognostic significance of nutritional markers in metastatic gastric and esophageal adenocarcinoma. Cancer Medicine, 2021, 10, 199-207.	2.8	12
11	CT perfusion in peripheral arterial disease—hemodynamic differences before and after revascularisation. European Radiology, 2021, 31, 5507-5513.	4.5	11
12	Quantitative <sup>68</sup> Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with <sup>177</sup> Lu-DOTATATE. Journal of Nuclear Medicine, 2021, 62, 1406-1414.	5.0	40
13	Role of intravoxel incoherent motion parameters in gastroesophageal cancer: relationship with 18F-FDC-positron emission tomography, computed tomography perfusion and magnetic resonance perfusion imaging parameters. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2021, 65, 178-186.	0.7	0
14	Detection of clinically significant prostate cancer with 18F-DCFPyL PET/multiparametric MR. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3702-3711.	6.4	15
15	Deep learning for whole-body medical image generation. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3817-3826.	6.4	12
16	Predictors of survival after metastasectomy of oligometastatic recurrence following gastroesophageal cancer treatment. Journal of Clinical Oncology, 2021, 39, e16060-e16060.	1.6	0
17	Neuroendocrine Tumors. PET Clinics, 2021, 16, 353-364.	3.0	3
18	18F-DCFPyL (PSMA) PET in the Management of Men with Biochemical Failure after Primary Therapy: Initial Clinical Experience of an Academic Cancer Center. Current Oncology, 2021, 28, 3251-3258.	2.2	2

#	Article	IF	CITATIONS
19	A Pre-TACE Radiomics Model to Predict HCC Progression and Recurrence in Liver Transplantation: A Pilot Study on a Novel Biomarker. Transplantation, 2021, 105, 2435-2444.	1.0	20
20	The association between lesion tracer uptake on 68Ga-DOTATATE PET with morphological response to 177Lu-DOTATATE therapy in patients with progressive metastatic neuroendocrine tumors. Nuclear Medicine Communications, 2021, Publish Ahead of Print, 73-77.	1.1	3
21	Combined simultaneous FDG-PET/MRI with T1 and T2 mapping as an imaging biomarker for the diagnosis and prognosis of suspected cardiac sarcoidosis. European Journal of Hybrid Imaging, 2021, 5, 24.	1.5	31
22	Evaluation of 18Fâ€FDG PET/CT as an early imaging biomarker for response monitoring after radiochemotherapy using cetuximab in head and heck squamous cell carcinoma. Head and Neck, 2020, 42, 163-170.	2.0	7
23	Convolutional neural networks for improving image quality with noisy PET data. EJNMMI Research, 2020, 10, 105.	2.5	47
24	PET/Magnetic Resonance Imaging Applications in Abdomen and Pelvis. Magnetic Resonance Imaging Clinics of North America, 2020, 28, 369-380.	1.1	9
25	Prognostic value of O-(2-[ <sup>18</sup> F]-fluoroethyl)-L-tyrosine PET in relapsing oligodendroglioma. Acta Oncológica, 2020, 59, 1357-1364.	1.8	0
26	Nuclear medicine and molecular imaging advances in the 21st century. British Journal of Radiology, 2020, 93, 20200095.	2.2	42
27	The impact of atlas-based MR attenuation correction on the diagnosis of FDG-PET/MR for Alzheimer's diseases— A simulation study combining multi-center data and ADNI-data. PLoS ONE, 2020, 15, e0233886.	2.5	6
28	<sup>18</sup> F-DCFPyL PET/CT in Patients with Subclinical Recurrence of Prostate Cancer: Effect of Lesion Size, Smoothing Filter, and Partial-Volume Correction on PROMISE Criteria. Journal of Nuclear Medicine, 2020, 61, 1615-1620.	5.0	4
29	Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study. Radiotherapy and Oncology, 2020, 150, 62-69.	0.6	3
30	Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer. Canadian Urological Association Journal, 2020, 15, 162-172.	0.6	12
31	Outcomes relative to paclitaxel dose-intensity when administered with ramucirumab in gastric and gastroesophageal junction (GEJ) adenocarcinoma Journal of Clinical Oncology, 2020, 38, e16539-e16539.	1.6	0
32	Prognostic significance of nutritional markers in metastatic gastric and esophageal adenocarcinoma Journal of Clinical Oncology, 2020, 38, 4557-4557.	1.6	0
33	Title is missing!. , 2020, 15, e0233886.		0
34	Title is missing!. , 2020, 15, e0233886.		0
35	Title is missing!. , 2020, 15, e0233886.		0

#	Article	IF	CITATIONS
37	Driving the Future of Nuclear Medicine. Journal of Nuclear Medicine, 2019, 60, 1S-2S.	5.0	9
38	CT-perfusion in peripheral arterial disease – Correlation with angiographic and hemodynamic parameters. PLoS ONE, 2019, 14, e0223066.	2.5	14
39	Interchangeability of radiomic features between [18F]â€ <scp>FDG PET</scp> / <scp>CT</scp> and [18F]â€ <scp>FDG PET</scp> / <scp>MR</scp> . Medical Physics, 2019, 46, 1677-1685.	3.0	22
40	Editorial commentary: Imaging the aorta for inflammation: Informing practice on emerging molecular techniques. Trends in Cardiovascular Medicine, 2019, 29, 449-450.	4.9	0
41	EJNMMI supplement: bringing AI and radiomics to nuclear medicine. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2627-2629.	6.4	10
42	Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2019, 191, 289-297.	1.3	15
43	Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation. Nuklearmedizin - NuclearMedicine, 2019, 58, 68-76.	0.7	20
44	<sup>18</sup> Fâ€FDG PET/CT for locoregional surveillance following definitive treatment of head and neck cancer: A metaâ€analysis of reported studies. Head and Neck, 2019, 41, 551-561.	2.0	24
45	Comparison of MRI Sequences in Whole-Body PET/MRI for Staging of Patients With High-Risk Prostate Cancer. American Journal of Roentgenology, 2019, 212, 377-381.	2.2	17
46	Prognostic significance of malnutrition in metastatic esophageal squamous cell carcinoma Journal of Clinical Oncology, 2019, 37, 171-171.	1.6	1
47	Radiomics in nuclear medicine and hybrid imaging: current standings on clinical applicability. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 321-322.	0.7	Ο
48	<sup>18</sup> F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center. British Journal of Radiology, 2018, 91, 20170814.	2.2	10
49	Influence of inter-observer delineation variability on radiomics stability in different tumor sites. Acta Oncológica, 2018, 57, 1070-1074.	1.8	152
50	Value of 18F-FET PET in adult brainstem glioma. Clinical Imaging, 2018, 51, 68-75.	1.5	8
51	Pulmonary nodule detection in oncological patients – Value of respiratory-triggered, periodically rotated overlapping parallel T2-weighted imaging evaluated with PET/CT-MR. European Journal of Radiology, 2018, 98, 165-170.	2.6	13
52	Reduction of <sup>18</sup> F-FDG Dose in Clinical PET/MR Imaging by Using Silicon Photomultiplier Detectors. Radiology, 2018, 286, 249-259.	7.3	59
53	Impact of time-of-flight PET on quantification accuracy and lesion detection in simultaneous 18F-choline PET/MRI for prostate cancer. EJNMMI Research, 2018, 8, 41.	2.5	12
54	Value of PET/MRI for assessing tumor resectability in NSCLC—intra-individual comparison with PET/CT. British Journal of Radiology, 2018, , 20180379.	2.2	8

#	Article	IF	CITATIONS
55	18FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study. BMC Cancer, 2018, 18, 548.	2.6	25
56	Feasibility of <sup>18</sup> F-FDG Dose Reductions in Breast Cancer PET/MRI. Journal of Nuclear Medicine, 2018, 59, 1817-1822.	5.0	14
57	Exploratory Radiomics in Computed Tomography Perfusion of Prostate Cancer. Anticancer Research, 2018, 38, 685-690.	1.1	29
58	Evaluation of multifunctional imaging parameters in gastro-oesophageal cancer using F-18-FDG-PET/CT with integrated perfusion CT. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2018, , .	0.7	1
59	Effect of Time-of-Flight Information on PET/MR Reconstruction Artifacts: Comparison of Free-breathing versus Breath-hold MR-based Attenuation Correction. Radiology, 2017, 282, 229-235.	7.3	16
60	The Effect of Susceptibility Artifacts Related to Metallic Implants on Adjacent-Lesion Assessment in Simultaneous TOF PET/MR. Journal of Nuclear Medicine, 2017, 58, 1167-1173.	5.0	8
61	PET+MR versus PET/CT in the initial staging of head and neck cancer, using a trimodality PET/CT+MR system. Clinical Imaging, 2017, 42, 232-239.	1.5	43
62	Comparison of Contrast-Enhanced CT and [18F]FDG PET/CT Analysis Using Kurtosis and Skewness in Patients with Primary Colorectal Cancer. Molecular Imaging and Biology, 2017, 19, 795-803.	2.6	32
63	Local resectability assessment of head and neck cancer: Positron emission tomography/MRI versus positron emission tomography/CT. Head and Neck, 2017, 39, 1550-1558.	2.0	35
64	EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 17-31.	6.4	206
65	Clinical evaluation of TOF versus non-TOF on PET artifacts in simultaneous PET/MR: a dual centre experience. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1223-1233.	6.4	20
66	Clinical evaluation of a block sequential regularized expectation maximization reconstruction algorithm in 18F-FDG PET/CT studies. Nuclear Medicine Communications, 2017, 38, 57-66.	1.1	42
67	The Effect of Defective PET Detectors in Clinical Simultaneous [18F]FDG Time-of-Flight PET/MR Imaging. Molecular Imaging and Biology, 2017, 19, 626-635.	2.6	5
68	Optimizing a perfusion CT protocol for head and neck cancer. Current Directions in Biomedical Engineering, 2017, 3, 591-594.	0.4	1
69	Assessment of prostate cancer with integrated CT-perfusion using a sector-wise approach. Turkish Journal of Urology, 2017, 43, 152-157.	1.3	1
70	Clinical Evaluation of Zero-Echo-Time Attenuation Correction for Brain <sup>18</sup> F-FDG PET/MRI: Comparison with Atlas Attenuation Correction. Journal of Nuclear Medicine, 2016, 57, 1927-1932.	5.0	102
71	Evaluation of Atlas-Based Attenuation Correction for Integrated PET/MR in Human Brain: Application of a Head Atlas and Comparison to True CT-Based Attenuation Correction. Journal of Nuclear Medicine, 2016, 57, 215-220.	5.0	80
72	Multi-Atlas–Based Attenuation Correction for Brain 18F-FDG PET Imaging Using a Time-of-Flight PET/MR Scanner: Comparison with Clinical Single-Atlas– and CT-Based Attenuation Correction. Journal of Nuclear Medicine, 2016, 57, 1258-1264.	5.0	29

#	Article	IF	CITATIONS
73	Effect of Attenuation Correction on Regional Quantification Between PET/MR and PET/CT: A Multicenter Study Using a 3-Dimensional Brain Phantom. Journal of Nuclear Medicine, 2016, 57, 818-824.	5.0	11
74	Diagnostic accuracy of sequential co-registered PET+MR in comparison to PET/CT in local thoracic staging of malignant pleural mesothelioma. Lung Cancer, 2016, 94, 40-45.	2.0	21
75	TNM Staging of Non–Small Cell Lung Cancer: Comparison of PET/MR and PET/CT. Journal of Nuclear Medicine, 2016, 57, 21-26.	5.0	65
76	Histogram Analysis of CT Perfusion of Hepatocellular Carcinoma for Predicting Response to Transarterial Radioembolization: Value of Tumor Heterogeneity Assessment. CardioVascular and Interventional Radiology, 2016, 39, 400-408.	2.0	27
77	Osseous vitality in single photon emission computed tomography/computed tomography (SPECT/CT) after balloon tibioplasty of the tibial plateau: a case series. BMC Medical Imaging, 2015, 15, 56.	2.7	4
78	Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT. BMC Cancer, 2015, 15, 1002.	2.6	42
79	Combined PET/CT-perfusion in patients with head and neck cancers might predict failure after radio-chemotherapy: a proof of concept study. BMC Medical Imaging, 2015, 15, 60.	2.7	7
80	Intra-individual comparison of PET/CT with different body weight-adapted FDG dosage regimens. Acta Radiologica Open, 2015, 4, 204798161456007.	0.6	9
81	Workflow in Simultaneous PET/MRI. Seminars in Nuclear Medicine, 2015, 45, 332-344.	4.6	32
82	Guest Editorial. Seminars in Nuclear Medicine, 2015, 45, 189-191.	4.6	6
83	Pitfalls and Limitations in Simultaneous PET/MRI. Seminars in Nuclear Medicine, 2015, 45, 552-559.	4.6	16
84	Clinical evaluation of PET image quality as a function of acquisition time in a new TOF-PET/MR compared to TOF-PET/CT - initial results. EJNMMI Physics, 2015, 2, A76.	2.7	3
85	Tumor stage, tumor site and HPV dependent correlation of perfusion CT parameters and [18F]-FDC uptake in head and neck squamous cell carcinoma. Radiotherapy and Oncology, 2015, 117, 125-131.	0.6	18
86	Hybrid PET/MR Imaging: An Algorithm to Reduce Metal Artifacts from Dental Implants in Dixon-Based Attenuation Map Generation Using a Multiacquisition Variable-Resonance Image Combination Sequence. Journal of Nuclear Medicine, 2015, 56, 93-97.	5.0	28
87	Dose Optimization in TOF-PET/MR Compared to TOF-PET/CT. PLoS ONE, 2015, 10, e0128842.	2.5	30
88	Post-treatment surveillance of head and neck cancer: pitfalls in the interpretation of FDG PET-CT/MRI. Swiss Medical Weekly, 2015, 145, w14116.	1.6	11
89	Clinical image quality perception and its relation to NECR measurements in PET. EJNMMI Physics, 2014, 1, 103.	2.7	15
90	Whole-Body Nonenhanced PET/MR versus PET/CT in the Staging and Restaging of Cancers: Preliminary Observations. Radiology, 2014, 273, 859-869.	7.3	78

#	Article	IF	CITATIONS
91	Metal artifact reduction in patients with dental implants using multispectral three-dimensional data acquisition for hybrid PET/MRI. EJNMMI Physics, 2014, 1, 102.	2.7	36
92	PET/MRI and PET/CT in follow-up of head and neck cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1066-75.	6.4	68
93	Generation of pseudo-CT from a single MRI for PET/MR attenuation correction purposes. EJNMMI Physics, 2014, 1, A74.	2.7	2
94	Dynamic comparison of PET imaging performance between state-of-the-art ToF-PET/CT and ToF-PET/MR scanners. EJNMMI Physics, 2014, 1, A75.	2.7	1
95	Cluster-based segmentation of dual-echo ultra-short echo time images for PET/MR bone localization. EJNMMI Physics, 2014, 1, 7.	2.7	18
96	Contrast-Enhanced PET/MR Imaging Versus Contrast-Enhanced PET/CT in Head and Neck Cancer: How Much MR Information Is Needed?. Journal of Nuclear Medicine, 2014, 55, 551-558.	5.0	123
97	The clinical rehabilitation of spine and spinal cord disorders: detection and evaluation using SPECT/CT. Neural Regeneration Research, 2014, 9, 795.	3.0	5
98	Evaluation of MR acquisition strategies for MR based attenuation correction. , 2013, , .		0
99	Combined PET/CT-perfusion in patients with head and neck cancers. European Radiology, 2013, 23, 163-173.	4.5	18
100	Clinical value of a combined multi-phase contrast enhanced DOPA-PET/CT in neuroendocrine tumours with emphasis on the diagnostic CT component. European Radiology, 2011, 21, 256-264.	4.5	8